Mechanism of Action
APJ Receptor Activation
Apelin-36 binds the APJ receptor with lower affinity than apelin-13 or apelin-17 but with a longer duration of action. APJ is a Gi-coupled GPCR that inhibits adenylate cyclase, reduces cAMP, and activates PI3K/Akt and MAPK pathways. In the cardiovascular system, APJ activation on cardiomyocytes and vascular smooth muscle cells produces positive inotropy and vasodilation respectively.
Fluid Homeostasis
The apelin/APJ axis counterbalances vasopressin (AVP/ADH) in fluid homeostasis. Apelin-36 reduces AVP-stimulated water reabsorption in collecting ducts and inhibits AVP release from the posterior pituitary. This diuretic effect without electrolyte wasting makes the apelin system attractive for heart failure management where both fluid overload and neurohormonal activation are present.
Research Summary
Pulmonary Arterial Hypertension
Phase 2Apelin-36 levels are reduced in pulmonary arterial hypertension (PAH), and APJ receptor expression is decreased in pulmonary vascular beds of PAH patients. Phase 2 trials of apelin analogs in PAH showed improvements in hemodynamics and exercise capacity. A synthetic apelin analog (MM07) showed encouraging results in a Phase 2 trial for PAH.
Heart Failure
PreclinicalApelin-36 infusion improves cardiac output, reduces filling pressures, and decreases peripheral vascular resistance in preclinical heart failure models. Human heart failure patients show significantly reduced plasma apelin levels. Phase 2 trials of apelin-13 infusion in heart failure patients demonstrated sustained hemodynamic improvements.
Calculate your Apelin-36 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Hemodynamic improvement | 4 nmol/kg/min IV | 15-min infusion | Intravenous |
| Diuresis research | 1-10 nmol/kg SC | Single | Subcutaneous |
No approved apelin therapy. Synthetic APJ agonists are in Phase 2 development for PAH and heart failure.
Interactions
Safety Profile
Apelin-36 IV infusion causes dose-dependent vasodilation with risk of hypotension at higher doses. Tachycardia may occur from reflex sympathetic activation. No arrhythmias or QTc prolongation identified in clinical studies. Short plasma half-life limits cumulative exposure. No long-term safety data available.
References
- [1]Tatemoto K et al. (1998). Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochemical and Biophysical Research Communications, 251(2), 471-476.
- [2]Cheng W et al. (2019). Apelin peptides as cardiovascular therapeutics. Current Medicinal Chemistry, 26(3), 443-458.